Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.
Geron Corporation (GERN) is a clinical-stage biopharmaceutical company advancing novel oncology therapies through its telomerase inhibitor research. This page provides investors and industry professionals with verified updates on clinical developments, regulatory milestones, and strategic initiatives.
Access the latest press releases and analysis related to imetelstat's progress in treating hematologic malignancies like myelodysplastic syndromes. Our curated collection ensures you stay informed about trial results, partnership announcements, and scientific presentations without speculative commentary.
Key updates include details on Phase 3 clinical trials, FDA communications, intellectual property developments, and collaboration agreements. All content is sourced directly from official company channels to maintain accuracy and compliance.
Bookmark this page for streamlined access to Geron's evolving story in cancer therapeutics. Check back regularly for objective reporting on advancements in telomerase-targeted treatment approaches.
Geron Corporation (NASDAQ: GERN) plans to conduct an underwritten public offering of its common stock and pre-funded warrants. The offering is subject to market conditions and no guarantee of completion exists. Stifel and Baird are joint book-running managers, with Needham & Company acting as the lead manager. A shelf registration statement has been filed with the SEC, and a preliminary prospectus will be available. Geron focuses on developing imetelstat, a telomerase inhibitor, for hematologic malignancies, currently in two Phase 3 trials.
Geron Corporation (Nasdaq: GERN) announced the grant of non-statutory stock options for 320,000 shares of common stock to new employees as inducements for their commencement of employment. The options, set at an exercise price of $1.03 per share, have a 10-year term and will vest over four years. This grant adheres to Nasdaq Listing Rule 5635(c)(4) and is part of Geron's 2018 Inducement Award Plan. The company is currently engaged in two Phase 3 clinical trials for its telomerase inhibitor, imetelstat, targeting hematologic malignancies.
Geron Corporation (Nasdaq: GERN) announced key business updates and financial results for Q4 and FY 2021. The company reported a net loss of $32 million for Q4 2021 and $116.1 million for the year, with revenues of $1 million for Q4 and $1.4 million for the year. Geron ended 2021 with $212.7 million in cash, supporting operations through Q1 2023. Upcoming milestones include top-line results from the IMerge Phase 3 trial in early January 2023 and plans to submit a New Drug Application for imetelstat in the US in 2023. The company anticipates expanding its clinical programs in 2022.
Geron Corporation (NASDAQ: GERN) will release its fourth quarter and full year 2021 financial results after market close on March 10, 2022. A conference call will be held at 4:30 p.m. ET on the same day to discuss the results and upcoming milestones. Investors can access the press release on the company’s website. Geron is focused on developing imetelstat, a telomerase inhibitor, for hematologic malignancies, with ongoing Phase 3 clinical trials for lower risk myelodysplastic syndromes and refractory myelofibrosis.
Geron Corporation (NASDAQ: GERN) announced that its Chairman and CEO, John A. Scarlett, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on January 28, 2022, at 11:00 a.m. ET. A live webcast of the presentation will be available on Geron's Investor Relations website and archived for 30 days after the event. Geron focuses on developing imetelstat, a first-in-class telomerase inhibitor, for treating hematologic malignancies, currently conducting two Phase 3 clinical trials: IMerge and IMpactMF.
Geron Corporation (NASDAQ: GERN) announced the grant of non-statutory stock options totaling 435,800 shares to new employees as an inducement for employment. These options were issued on January 19, 2022, with an exercise price of $1.10 per share, aligning with the stock's closing price. The options have a 10-year term and vest over four years, starting with 12.5% after six months and the remainder in equal installments. This action is in compliance with Nasdaq regulations and is part of Geron's 2018 Inducement Award Plan.
Geron is focusing on developing imetelstat, a telomerase inhibitor, for hematologic malignancies.
Geron Corporation (Nasdaq: GERN), a biopharmaceutical company, announced that CEO John A. Scarlett will present at the H.C. Wainwright BioConnect Conference. The pre-recorded presentation will be accessible starting at 7 a.m. ET on January 10, 2022, via a provided link and will be archived for 30 days post-event. Geron focuses on a first-in-class telomerase inhibitor, imetelstat, currently in two Phase 3 clinical trials: IMerge for lower risk myelodysplastic syndromes and IMpactMF for refractory myelofibrosis.
Geron Corporation (Nasdaq: GERN) announced the grant of a non-statutory stock option for 50,000 shares of common stock to a newly hired employee, effective December 15, 2021. The option has an exercise price of $1.37 per share, matching the stock's closing price on that date. It carries a 10-year term and vests over four years, with 12.5% vesting after six months and the remainder in equal installments over the next 42 months, subject to continued employment. This grant adheres to Nasdaq Listing Rule 5635(c)(4) and is part of Geron's 2018 Inducement Award Plan.
Geron Corporation (GERN) announced three poster presentations at the 63rd American Society of Hematology Annual Meeting regarding imetelstat, its novel telomerase inhibitor. The posters showcase ongoing Phase 3 trials for imetelstat in lower risk myelodysplastic syndromes (MDS) and refractory myelofibrosis (MF), emphasizing its potential clinical benefits and safety. Results from the IMerge Phase 3 trial are expected in early January 2023, while the IMpactMF trial continues patient enrollment. Imetelstat has received Fast Track designation from the FDA for specific hematological conditions.
Geron Corporation (NASDAQ: GERN) announces the appointment of Edward Koval as Executive Vice President and Chief Business Officer, enhancing its executive team. Koval brings over 25 years of biotech experience and will focus on business development related to Geron's imetelstat and telomerase inhibitor franchises. Top-line results from the IMerge Phase 3 trial are expected in 13 months, while an interim analysis of the IMpactMF trial is anticipated in 2024. This leadership shift aims to maximize the potential of Geron's innovative treatments in hematologic malignancies.
